Business Description
Vanda Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US9216591084
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 41.29 | |||||
Equity-to-Asset | 0.84 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.86 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 2.33 | |||||
Beneish M-Score | -2.24 | |||||
WACC vs ROIC |
Growth Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -9.4 | |||||
3-Year EPS without NRI Growth Rate | -54.3 | |||||
3-Year FCF Growth Rate | -38 | |||||
3-Year Book Growth Rate | 4.7 |
Momentum Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 24.92 | |||||
9-Day RSI | 18.53 | |||||
14-Day RSI | 15.84 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.94 | |||||
Quick Ratio | 4.92 | |||||
Cash Ratio | 4.43 | |||||
Days Inventory | 28.33 | |||||
Days Sales Outstanding | 58.76 | |||||
Days Payable | 144.52 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.6 | |||||
Shareholder Yield % | 0.46 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 92.32 | |||||
Operating Margin % | -7.24 | |||||
Net Margin % | 1.3 | |||||
FCF Margin % | 6.45 | |||||
ROE % | 0.47 | |||||
ROA % | 0.39 | |||||
ROIC % | -2.9 | |||||
ROC (Joel Greenblatt) % | -139.39 | |||||
ROCE % | -2.52 | |||||
Years of Profitability over Past 10-Year | 7 |
GF Value Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 96.92 | |||||
PE Ratio without NRI | 96.92 | |||||
Shiller PE Ratio | 18.94 | |||||
Price-to-Owner-Earnings | 105 | |||||
PS Ratio | 1.51 | |||||
PB Ratio | 0.53 | |||||
Price-to-Tangible-Book | 0.68 | |||||
Price-to-Free-Cash-Flow | 23.23 | |||||
Price-to-Operating-Cash-Flow | 22.6 | |||||
EV-to-EBIT | 6.13 | |||||
EV-to-EBITDA | 7.82 | |||||
EV-to-Revenue | -0.44 | |||||
EV-to-FCF | -6.89 | |||||
Price-to-Projected-FCF | 0.38 | |||||
Price-to-Median-PS-Value | 0.37 | |||||
Price-to-Graham-Number | 1.72 | |||||
Price-to-Net-Current-Asset-Value | 0.88 | |||||
Price-to-Net-Cash | 1.02 | |||||
Earnings Yield (Greenblatt) % | 16.31 | |||||
FCF Yield % | 4.23 | |||||
Forward Rate of Return (Yacktman) % | -3.35 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Vanda Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 192.64 | ||
EPS (TTM) ($) | 0.052 | ||
Beta | -0.42 | ||
Volatility % | 45.45 | ||
14-Day RSI | 15.84 | ||
14-Day ATR ($) | 0.332132 | ||
20-Day SMA ($) | 7.69195 | ||
12-1 Month Momentum % | 0 | ||
52-Week Range ($) | 4.685 - 10.39 | ||
Shares Outstanding (Mil) | 58.2 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 6 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Vanda Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Vanda Pharmaceuticals Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Vanda Pharmaceuticals Inc Frequently Asked Questions
What is Vanda Pharmaceuticals Inc(LTS:0LKB)'s stock price today?
When is next earnings date of Vanda Pharmaceuticals Inc(LTS:0LKB)?
Does Vanda Pharmaceuticals Inc(LTS:0LKB) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |